We will be attending the 17th Annual Next Generation Summit, taking place Aug18-20 in Washington, D.C.
Don’t miss our presentation in the Early Cancer Surveillance track, with the topic: Multi- and Single-Cancer Early Detection: Validation of Improved Early Screening.
Talk Title: Epigenomic Signals Enable Early Cancer Detection in Liquid Biopsies
When: Monday, August 18 – 9:00 am
Presenter: Anna Bergamaschi, PhD, Vice President Product R&D, ClearNote Health
Detection of cancer using molecular methods has proven challenging due to low tumor burden associated with early-stage cancers. This presentation will showcase a new technology workflow developed by ClearNote Health that leverages epigenomics and genomics changes in circulating free-DNA, in combination with machine learning, to enable early detection in both single cancer and multi-cancer modalities. We will also provide an update on the ongoing clinical strategy supporting the clinical validation and utility of single and multi-cancer tests